سوق الركبة العظمية في أوروبا – اتجاهات الصناعة والتوقعات حتى عام 2029

تحليل السوق والرؤى

الركبة هي أكبر مفصل في الجسم. تفصل بين عظام الركبة العلوية والسفلية غضاريف هلالية. وتتصل عظمة الساق العلوية (عظم الفخذ) وعظام الساق السفلية (الظنبوب والشظية) بالأربطة والأوتار. وهناك عدة أسباب تستلزم استخدام أدوات الركبة التقويمية مثل غرسات الركبة، وتقويم العظام، والمساعدات، واستخدام الأدوية مثل المسكنات والأدوية المضادة للالتهابات غير الستيرويدية. والسبب الشائع لجراحة استبدال الركبة هو تخفيف الألم الشديد الناجم عن هشاشة العظام، وتمزق الأربطة الحاسمة والجانبية، وإصابات الغضروف الهلالي. وعادة ما يعاني الأشخاص الذين يحتاجون إلى جراحة استبدال الركبة من مشاكل في المشي، وصعود السلالم، والدخول والخروج من الكراسي. كما يعاني البعض من آلام الركبة أثناء الراحة.

تعريف السوق

في أوروبا، تستمر الأمراض العظمية في الارتفاع في جميع أنحاء العالم. مرض الركبة الأكثر شيوعًا في أوروبا هو هشاشة العظام في الركبة. يشكل هشاشة العظام في الركبة ما يقرب من أربعة أخماس عبء هشاشة العظام (OA) في جميع أنحاء العالم ويزداد مع السمنة والعمر. أمراض الركبة، وخاصة هشاشة العظام في الركبة، شائعة وسبب رئيسي للإعاقة بين كبار السن. حتى الآن، ثبت أن هشاشة العظام في الركبة قابلة للشفاء باستثناء عملية استبدال الركبة التي تعتبر علاجًا فعالًا في مرحلة متقدمة من المرض. تتضمن جراحة استبدال الركبة شق وإزالة العظم التالف من عظم الفخذ للمريض وركبة الركبة واستبداله بمفصل اصطناعي (أطراف صناعية وغرسات)، وهي غرسات متحركة وثابتة. تتكون الأطراف الصناعية والغرسات من المعدن والسيراميك والبلاستيك. يتم إصلاح الأربطة عن طريق وضعها مرة أخرى على العظم الأصلي في وضعها التشريحي، وذلك باستخدام مرساة صغيرة لربط الأربطة بالعظم.

تشير تحليلات Data Bridge Market Research إلى أن سوق الركبة العظمية في أوروبا سينمو بمعدل نمو سنوي مركب قدره 5.0٪ خلال الفترة المتوقعة من 2022 إلى 2029.

 Europe Orthopedic Knee Market Dynamics

Drivers

• Rise in incidence of knee diseases

Orthopedic diseases continue to rise throughout the globe. The typical knee disease which occurs in Europe is knee osteoarthritis. Knee osteoarthritis accounts for almost four-fifths of osteoarthritis (OA) burden worldwide and increases with obesity and age. Knee diseases, especially knee osteoarthritis, are common and a significant cause of disability among the elderly population. Knee osteoarthritis can be treated easily in Europe. In Europe, a survey conducted by e-clinical medicine states that the prevalence of knee diseases in Europe was 19.2%.

For instance,

• In March 2020, according to a report by the Oxford Academic, the incidence of knee osteoarthritis was reported to show the highest number of cases in the U.K., followed by France, Germany, Spain, and Italy, showing the fewer record cases of knee osteoarthritis

Knee osteoarthritis is a common occurrence in Switzerland. The rise in the incidence of chronic knee disorders is expected to boost the sales and supply of medication and implants for the treatment of knees in Europe. It is expected to meet the patient's requirements. The knowledge about the prevalence and incidence of orthopedic knee diseases would help find novel solutions and aid in more collaborations and partnerships with market players based in countries in Europe.

• Rise in awareness about knee treatment in Europe

Cognizance of knee disorders, understanding, and scope of the treatment is a vital step to help and guide people suffering from osteoarthritis and meniscal injuries. It helps in achieving early detection and management. Public and private institutes' awareness about the symptoms and treatment of chronic knee diseases would result in timely treatment and provide the option to access inexpensive universal health aid and increased availability of rehabilitative therapy

For instance,

• In November 2020, the European Knee Society (EKS) had collaborated with the Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Italy, for organizing two fellowships and creating awareness about the treatment of primary and revision knee and hip replacement

From the above points, we can establish that awareness about the early treatment and use of knee implants would result in collaborations of market players with health institutions for the supply and distribution of the devices. This will result in a rise in product and business line expansion.

Opportunities

• Strategic Initiatives By Market Players

The need for medications to treat knee disorders in Europe has increased due to the rise in prevalence and incidence of chronic knee disorders, advanced therapies for knee osteoarthritis and meniscal injuries, and unmet medical needs. The factors (such as rise in incidence, cases of chronic knee disorders, and availability of advanced therapies) enhance the necessity for orthopedic rehabilitation therapy, and to achieve the market demand, minor and major market players are utilizing various strategies.

The major players are also trying to devise specific strategies, such as product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth running of the business, avoid risks, and increase the long-term growth in the sales of the market.

For instance,

• In June 2020, Zimmer Biomet received clearance from the Food and Drug Administration (FDA) for ROSA Hip System for Robotically-Assisted Direct Anterior Total Hip Arthroplasty. The clearance received had made the ROSA Hip System available for use by diagnostic centers in Europe and made it clear for post-marketing approval
• In December 2017, amplitude SURGICAL launched the ACLip, an innovation in anterior cruciate ligament (ACL) reconstruction knee surgery. The ACLip is a knee implant that provides surgeons an enhanced method to perform knee arthroscopy surgeries and is used as an outpatient procedure. The launch had increased the sales and revenue of the knee product segment, and the novel implant was distributed in orthopedic clinics in Europe

The growth of technological advancements in orthopedic knee implants

Total knee arthroplasty is a suitable treatment for severe osteoarthritis. Despite reasonable survival rates, up to 20% of real knee arthroplasty patients remain dissatisfied. Recently, promising new technologies have been developed in knee arthroplasty and could improve functional outcomes. The robotic-assisted systems allow an accurate and reproducible bone preparation due to robotic assistance, with a 3D surgical planning, based on preoperative 3D imaging or not.

For instance,

• In November 2021, Smith & Nephew launched the turnkey' robotic-assisted surgical system; an advanced system for total and partial knee arthroplasties. The turnkey robotic surgical system was designed to measure, plan, and perform a knee surgery that is personalized to the patient's anatomy

Novel technologies are expected to improve diagnosis, risk stratification, and disease monitoring of meniscal injuries and osteoarthritis. The innovative combined drug therapies are expected to improve patient outcomes in the coming years. Hence, the use of innovative treatments is expected to create lucrative opportunities for the Europe orthopedic knee market

Restraints/Challenges

• Problems Faced While Using Orthopedic Knee Medications and Implants

Orthopedic specialists observe certain risks while using the implants and consuming the medications. The knee replacement surgeries deliver complications that arise from surgery or a faulty implant. The implant becoming loose is one of the most severe complications after knee surgery, and pain is the most common one. Loosening can cause bone fractures, instability, and serious falls. Almost all serious complications require revision surgery. The risks faced are mechanical risks, knee implant loosening and physical pain.

For instance,

• The risks incurred while using the orthopedic ceramic knee implants are implant failure due to induced aseptic loosening and hypersensitivity
• The complications occurred in metal implants after surgery are loosening, instability, dislocation, misalignment, and device failure, which can result from manufacturing defects, poorly fitted implants, or problems during surgery

The risks that occur while using the knee implants and consuming the medication would decrease the usage and supply of the knee implants and bracing and supporting devices. This may lead to a decline in sales of implants and drugs. Therefore, the risks related to knee medications and implants are expected to hinder the market growth.

• Lack of skilled professionals

The lack or shortage of skilled expertise would challenge the pace of recovery and growth in one place. Often, the unemployed people in one place have skills that are in short supply elsewhere. Moreover, rapid technological advancement in this field also leads to a lack of expertise. Despite the call to increase, the number of podiatrists in Europe and several residency training programs remain unknown.

For instance,

• In England, the data by the National Center of Biotechnology Information (NCBI) state that joint arthroplasty service has substantially declined over recent weeks throughout Europe

As skill demands are too high, it has manifested as a challenge to retain and manage skill-specified professionals. Moreover, technological advancement is another aspect that leads to the increased demand for skilled professionals

The Europe orthopedic knee market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Europe orthopedic knee market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

The data by the Academic coup states that around four million people suffer from knee osteoarthritis, across Europe and has a lifetime risk of 45% for knee osteoarthritis.

Europe orthopedic knee market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on the Europe Orthopedic Knee Market

The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the diagnosis management and treatment. The lack of access to orthopaedic clinics will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in the treatment of chronic knee injuries during the pandemic.

Recent Development

• In March, DePuy Synthes had added two more orthopedic knee products in its portfolio, to the Attune knee portfolio, during the pandemic. The two products which were added are the cementless fixed bearing knee and medial stabilized knee to it’s attune knee portfolio. The addition of the new orthopedic knee products increased the product segment revenue and increased the market size in Europe region

Europe Orthopedic Knee Market Scope

The Europe orthopedic knee market is segmented on the basis of product type, indication and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Knee arthroscopy
• Ligament Repair
• Others

On the basis of product type, the market is segmented into knee arthroscopy, ligament repair and others.

Indication

• Osteoarthritis
• Cruciate And Collateral Ligament Tears
• Meniscal Injuries
• Others

على أساس الإشارة، تم تقسيم السوق إلى هشاشة العظام ، وتمزقات الرباط الصليبي والجانبي، وإصابات الغضروف الهلالي وغيرها

المستخدم النهائي

• المستشفيات
• مراكز إعادة التأهيل
• مراكز العظام
• مراكز الجراحة الخارجية
• آحرون

على أساس المستخدم النهائي، يتم تقسيم السوق إلى المستشفيات ومراكز إعادة التأهيل ومراكز العظام ومراكز الجراحة الخارجية وغيرها.

تحليل/رؤى إقليمية لسوق الركبة العظمية في أوروبا

يتم تحليل سوق الركبة العظمية في أوروبا ويتم توفير رؤى حجم السوق والاتجاهات حسب البلد ونوع المنتج والمؤشر والمستخدم النهائي، كما هو مذكور أعلاه.

الدول التي يغطيها تقرير سوق جراحة الركبة العظمية في أوروبا هي ألمانيا وفرنسا والمملكة المتحدة وإسبانيا وإيطاليا وتركيا وهولندا وبلجيكا وسويسرا وبقية أوروبا. ومن المتوقع أن تهيمن ألمانيا على السوق بسبب ارتفاع حالات هشاشة العظام في الركبة وارتفاع جراحات استبدال الركبة ووجود العديد من مراكز جراحة العظام في ألمانيا.

يقدم قسم الدولة في التقرير أيضًا عوامل التأثير الفردية على السوق والتغييرات في اللوائح في السوق محليًا والتي تؤثر على الاتجاهات الحالية والمستقبلية للسوق. تعد نقاط البيانات مثل المبيعات الجديدة ومبيعات الاستبدال والتركيبة السكانية للدولة وعلم الأوبئة المرضية وتعريفات الاستيراد والتصدير من بين المؤشرات الرئيسية المستخدمة للتنبؤ بسيناريو السوق للدول الفردية. أيضًا، يتم النظر في وجود وتوافر العلامات التجارية العالمية والتحديات التي تواجهها بسبب المنافسة الكبيرة أو النادرة من العلامات التجارية المحلية والمحلية وتأثير قنوات المبيعات أثناء تقديم تحليل التوقعات لبيانات الدولة.

تحليل المنافسة وحصة سوق جراحة الركبة العظمية في أوروبا

يقدم المشهد التنافسي لسوق الركبة العظمية في أوروبا تفاصيل حسب المنافس. تتضمن التفاصيل نظرة عامة على الشركة، والبيانات المالية للشركة، والإيرادات المتولدة، وإمكانات السوق، والاستثمار في البحث والتطوير، ومبادرات السوق الجديدة، والحضور العالمي، ومواقع الإنتاج والمرافق، والقدرات الإنتاجية، ونقاط القوة والضعف في الشركة، وإطلاق المنتج، وعرض المنتج ونطاقه، وهيمنة التطبيق. ترتبط نقاط البيانات المذكورة أعلاه فقط بتركيز الشركات فيما يتعلق بسوق الركبة العظمية في أوروبا.

بعض اللاعبين الرئيسيين العاملين في سوق الركبة العظمية في أوروبا هم Smith & Nephew و Össur و OTTOBOCK و DePuy Synthes (شركة تابعة لشركة Johnson & Johnson Private Limited) و GROUP FH ORTHO و Stryker و Zimmer Biomet. و B. Braun Melsungen AG و aap Implantate AG و MicroPort Orthopedics، Inc. و Exactech، Inc. و Medacta International و Aequos Endoprothetik GmbH و Symbios Orthopédie SA و PETER BREHM GmbH و Bayer AG و alloPlus GmbH و Bauerfeind USA Inc. و amplitude SURGICAL و CERAVER وغيرها.

SKU-68177